What caused Roche's Huntington's drug tominersen to hit the skids in late-stage test? It's complicated, analysts say

Just last month, Roche hit the pause button on a Phase III test for Huntington’s hopeful tominersen after a data committee questioned its risk/benefit profile. Now, the drugmaker is conducting an autopsy to see what went wrong, but answers are in short supply.